TILIM

The T cell immune response against latent infection with Mycobacterium tuberculosis

 Coordinatore STATENS SERUM INSTITUT 

 Organization address address: ARTILLERIVEJ 5
city: KOBENHAVN S
postcode: 2300

contact info
Titolo: Mrs.
Nome: Anne
Cognome: Enemark
Email: send email
Telefono: 4532683732
Fax: +45 32683035

 Nazionalità Coordinatore Denmark [DK]
 Totale costo 206˙629 €
 EC contributo 206˙629 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2009-IIF
 Funding Scheme MC-IIF
 Anno di inizio 2011
 Periodo (anno-mese-giorno) 2011-01-01   -   2012-12-31

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    STATENS SERUM INSTITUT

 Organization address address: ARTILLERIVEJ 5
city: KOBENHAVN S
postcode: 2300

contact info
Titolo: Mrs.
Nome: Anne
Cognome: Enemark
Email: send email
Telefono: 4532683732
Fax: +45 32683035

DK (KOBENHAVN S) coordinator 206˙629.00

Mappa

Leaflet | Map data © OpenStreetMap contributors, CC-BY-SA, Imagery © Mapbox

 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

epitopes       induced    latent    chronic    dominant    infection    tuberculosis    disease    subdominant    tb    infected    natural    eradicate    antigens    immune    re    activation    responses    ing   

 Obiettivo del progetto (Objective)

'One third of the world's population is infected with latent TB, which therefore constitutes the largest reservoir for TB. In 5% of latently infected individuals TB will eventually re-activate, and it is believed that most new TB cases is indeed due to re-activation of latent TB. TB is a chronic disease, and during the long interaction with the host, the immune response against TB antigens tend to focus on only a few dominant epitopes. The idea for the project is that while a response against the dominant epitopes will lead to partial protection, it is not enough to eradicate M.tb resulting in a lifelong latent infection. Moreover, a response against dominant epitopes will wane with time resulting in re-activation of TB, and spreading of the disease. As a consequence, an immune response against only dominant epitopes within M.tb antigens is not enough to fully control the infection and stop the spread of the disease.

Recently is has become increasingly clear that concerning chronic diseases, responses against subdominant epitopes, not induced by the natural infection, can be highly protective (1), and our working hypothesis is therefore the following: To increase the control over a chronic persisting M.tb infection (and prevent re-activation of TB), a response against the subdominant epitopes is required.

To examine this we intend to test the vaccine efficacy of both dominant epitopes (epitopes induced by the natural infection) and sub-dominant epitopes (epitopes not induced by the natural infection) given post exposure to animals harbouring a persistent infection.'

Introduzione (Teaser)

Vaccination against tuberculosis is largely inefficient as immune responses fail to eradicate the bacteria. European scientists proposed novel approaches for enhancing immune responses against Mycobacterium tuberculosis (Mtb) based on disease latency.

Altri progetti dello stesso programma (FP7-PEOPLE)

BIOFIB (2014)

Disordered assemblies of biofilaments: from aggregation to contractility

Read More  

MISFOLDED SOD1-ALS (2013)

Misfolded SOD1 Toxicity in Amyotrophic Lateral Sclerosis

Read More  

LIVCODE (2012)

Life-like visual information processing for robust collision detection

Read More